SCHEMBL9105896

SCHEMBL9105896

O=P(O)(O)Cc1ccc(Br)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.49
PGK1 P00558 1/20 0.47
PGK2 P07205 1/20 0.47
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GBA1 P04062 1/20 0.39
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
TSHR P16473 1/20 0.36
CA12 O43570 1/20 0.35
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.35
MMP8 P22894 1/20 0.35
MMP14 P50281 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butane SCHEMBL4025883 0.93 FDPS (0.44) FDPSPGK1PGK2KDM4EALDH1A1
SCHEMBL17915603 0.81 GBA1 (0.43) FDPSKDM4EALDH1A1GBA1MEN1
SCHEMBL14769117 0.78 PGK1 (0.48) PGK1PGK2
SCHEMBL28327869 0.78 FDPS (0.42) FDPSKDM4EALDH1A1GBA1MEN1
SCHEMBL14769151 0.77 PGK1 (0.47) PGK1PGK2CA12MMP2
SCHEMBL14769201 0.77 PGK1 (0.47) PGK1PGK2KDM4ERAB9A
Hydrochloric Acid SCHEMBL2637290 0.76 PGK1 (0.46) FDPSPGK1PGK2CA12
SCHEMBL1106224 0.74 GBA1 (0.41) FDPSKDM4EALDH1A1GBA1RAB9A
SCHEMBL30563036 0.74 GBA1 (0.41) FDPSKDM4EALDH1A1GBA1RAB9A
SCHEMBL14769155 0.73 PGK1 (0.47) PGK1PGK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3035929-B1 7A-AMIDE SUBSTITUTED-6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES MERCK SHARP & DOHME LLC (US) 2024-07-03 EP disclosed
EP-3035928-B1 3'-PYRIDYL SUBSTITUTED- 6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES MERCK SHARP & DOHME LLC (US) 2023-10-18 EP disclosed
US-10322140-B2 Preparation and use of 7a-heterocycle substituted-6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists MERCK SHARP & DOHME CORP. 2019-06-18 US disclosed
US-20180015106-A1 PREPARATION AND USE OF 7A-HETEROCYCLE SUBSTITUTED- 6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2018-01-18 US disclosed
US-9808473-B2 Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-11-07 US disclosed
US-20170240539-A1 Preparation and Use of Cyclic Sulfonamide Derivatives as PAR-1 Receptor Antagonists MERCK SHARP & DOHME CORP. (US) 2017-08-24 US disclosed
EP-3206687-A1 PREPARATION AND USE OF CYCLIC SULFONAMIDE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2017-08-23 EP disclosed
US-9701669-B2 Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-07-11 US disclosed
US-20160200713-A1 PREPARATION AND USE OF 3-PYRIDYL SUBSTITUTED- 6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-07-14 US disclosed
US-20160185764-A1 PREPARATION AND USE OF 7A-AMIDE SUBSTITUTED- 6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-06-30 US disclosed
EP-3035929-A1 7A-AMIDE SUBSTITUTED-6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES Merck Sharp & Dohme Corp. (US) 2016-06-29 EP disclosed
EP-3035928-A1 3'-PYRIDYL SUBSTITUTED- 6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES Merck Sharp & Dohme Corp. (US) 2016-06-29 EP disclosed
EP-3035930-A1 7A-HETEROCYCLE SUBSTITUTED- 6, 6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES Merck Sharp & Dohme Corp. (US) 2016-06-29 EP disclosed
WO-2016060940-A1 PREPARATION AND USE OF CYCLIC SULFONAMIDE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-04-21 WO disclosed
WO-2015026685-A1 7A-HETEROCYCLE SUBSTITUTED- 6, 6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2015-02-26 WO disclosed
WO-2015026686-A1 3'-PYRIDYL SUBSTITUTED- 6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2015-02-26 WO disclosed
WO-2015026693-A1 7A-AMIDE SUBSTITUTED-6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2015-02-26 WO disclosed
US-20120142690-A1 Substituted piperidines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10322140-B2 Preparation and use of 7a-heterocycle substituted-6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists F2R, F2RL1, BDKRB1 FDPS 2802/4885PGK1 3515/4885PGK2 4304/4885
US-20160185764-A1 PREPARATION AND USE OF 7A-AMIDE SUBSTITUTED- 6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS F2R, F2RL1, BDKRB1 FDPS 4441/4885PGK1 4501/4885PGK2 4792/4885
US-20160200713-A1 PREPARATION AND USE OF 3-PYRIDYL SUBSTITUTED- 6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS F2R, F2RL1, F2RL3 FDPS 3012/4885PGK1 3573/4885PGK2 4253/4885
US-20180015106-A1 PREPARATION AND USE OF 7A-HETEROCYCLE SUBSTITUTED- 6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS F2R, F2RL1, BDKRB1 FDPS 2802/4885PGK1 3515/4885PGK2 4304/4885
US-20120142690-A1 Substituted piperidines VHL, PIR, PIGO FDPS 313/4885PGK1 1216/4885PGK2 835/4885
US-20170240539-A1 Preparation and Use of Cyclic Sulfonamide Derivatives as PAR-1 Receptor Antagonists F2R, PRSS1, F2RL1 FDPS 2295/4885PGK1 2590/4885PGK2 2848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.